Clinical Characterisation and Comorbidities of Acquired Generalised Lipodystrophy: A 14-Year Follow-Up Study.

Acquired generalised lipodystrophy (AGL) is a rare disorder characterised by the gradual loss of fat that tends to generalise over time, the origin of which is still not fully clarified. The aim of this study was to offer a detailed description of seven patients with AGL (five women, 33.8 ± 18.6 years of age), evaluated over the last 14 years, in order to augment the knowledge of this disorder. The onset of the phenotype occurred during childhood and adolescence in five cases, and in adulthood in two cases. Three patients reported infections or vaccine administration prior to the development of lipodystrophy, and two subjects reported nodular swelling. The most frequent physical features were phlebomegaly, umbilical protrusion/hernia, and acanthosis nigricans. Skinfolds and body composition analysis showed the generalised absence of fat, with the exception of one patient in whom fat loss was spared in the trunk. The loss of fat in the palms/soles was observed in five subjects. Regarding metabolic comorbidities, throughout follow-up, two patients developed type 1 diabetes and one type 2 diabetes; three also presented hypertriglyceridaemia, one of whom developed acute pancreatitis, and no macrovascular complications were observed. Only one patient showed decreased complement C4. Autoimmunity was present in all cases, and six patients manifested Hashimoto's thyroiditis, type 1 diabetes, autoimmune hepatitis, and/or celiac disease. Thus, there are certain clinical characteristics of AGL that may be considered important diagnostic criteria to differentiate this disorder from other lipodystrophy subtypes.

Natural history and comorbidities of generalised and partial lipodystrophy syndromes in Spain.

The rarity of lipodystrophies implies that they are not well-known, leading to delays in diagnosis/misdiagnosis. The aim of this study was to assess the natural course and comorbidities of generalised and partial lipodystrophy in Spain to contribute to their understanding. Thus, a total of 140 patients were evaluated (77.1% with partial lipodystrophy and 22.9% with generalised lipodystrophy). Clinical data were collected in a longitudinal setting with a median follow-up of 4.7 (0.5-17.6) years. Anthropometry and body composition studies were carried out and analytical parameters were also recorded. The estimated prevalence of all lipodystrophies in Spain, excluding Köbberling syndrome, was 2.78 cases/million. The onset of phenotype occurred during childhood in generalised lipodystrophy and during adolescence-adulthood in partial lipodystrophy, with the delay in diagnosis being considerable for both cohorts. There are specific clinical findings that should be highlighted as useful features to take into account when making the differential diagnosis of these disorders. Patients with generalised lipodystrophy were found to develop their first metabolic abnormalities sooner and a different lipid profile has also been observed. Mean time to death was 83.8 ± 2.5 years, being shorter among patients with generalised lipodystrophy. These results provide an initial point of comparison for ongoing prospective studies such as the ECLip Registry study.

Should we suspect primary aldosteronism in patients with hypokalaemic rhabdomyolysis? A systematic review.

Severe hypokalaemia causing rhabdomyolysis (RML) in primary aldosteronism (PA) is a rare entity, and only a few cases have been reported over the last four decades. This systematic review and case report aims to gather all published data regarding a hypokalaemic RML as presentation of PA in order to contribute to the early diagnosis of this extremely rare presentation. With the use of PubMed Central, EMBASE, and Google Scholar, a thorough internet-based search of the literature was conducted to identify articles and cases with RML secondary to hypokalaemia due to PA between June 1976 and July 2023. The case study concerns a 68-year-old male patient with hypokalaemic RML at presentation of PA. In the systematic review of the literature, 37 cases of RML secondary to hypokalaemia due to PA have been reported to date. In summary, the median age was 47.5 years, the male/female ratio was 17/21, all patients presented symptoms (weakness and/or myalgia), all the patients were hypertensive, and only four patients had complications with acute kidney injury (AKI). Although PA rarely presents with RML, it should be suspected when marked hypokalaemia and hypertension are also present. Early detection and management are essential to reduce the frequency of manifestations such as AKI.

A murine model of BSCL2-associated Celia's encephalopathy.

Celia's encephalopathy or progressive encephalopathy with/without lipodystrophy is a neurodegenerative disease with a fatal prognosis in childhood. It is generally caused by the c.985C > T variant in the BSCL2 gene, leading to the skipping of exon 7 and resulting in an aberrant seipin protein (Celia-seipin). To precisely define the temporal evolution and the mechanisms involved in neurodegeneration, lipodystrophy and fatty liver in Celia's encephalopathy, our group has generated the first global knock-in murine model for the aberrant human transcript of BSCL2 (Bscl2Celia/Celia) using a strategy based on the Cre/loxP recombination system. In order to carry out a characterization at the neurological, adipose tissue and hepatic level, behavioral studies, brain PET, metabolic, histological and molecular studies were performed. Around 12% of homozygous and 5.4% of heterozygous knock-in mice showed severe neurological symptoms early in life, and their life expectancy was dramatically reduced. Severe generalized lipodystrophy and mild hepatic steatosis were present in these affected animals, while serum triglycerides and glucose metabolism were normal, with no insulin resistance. Furthermore, the study revealed a reduction in brain glucose uptake, along with patchy loss of Purkinje cells and the presence of intranuclear inclusions in cerebellar cortex cells. Homozygous, non-severely-affected knock-in mice showed a decrease in locomotor activity and greater anxiety compared with their wild type littermates. Bscl2Celia/Celia is the first murine model of Celia's encephalopathy which partially recapitulates the phenotype and severe neurodegenerative picture suffered by these patients. This model will provide a helpful tool to investigate both the progressive encephalopathy with/without lipodystrophy and congenital generalized lipodystrophy.

Clinical Spectrum of LMNA-Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review.

Type 2 familial partial lipodystrophy (FPLD2) is a laminopathic lipodystrophy due to pathogenic variants in the LMNA gene. Its rarity implies that it is not well-known. The aim of this review was to explore the published data regarding the clinical characterisation of this syndrome in order to better describe FPLD2. For this purpose, a systematic review through a search on PubMed until December 2022 was conducted and the references of the retrieved articles were also screened. A total of 113 articles were included. FPLD2 is characterised by the loss of fat starting around puberty in women, affecting limbs and trunk, and its accumulation in the face, neck and abdominal viscera. This adipose tissue dysfunction conditions the development of metabolic complications associated with insulin resistance, such as diabetes, dyslipidaemia, fatty liver disease, cardiovascular disease, and reproductive disorders. However, a great degree of phenotypical variability has been described. Therapeutic approaches are directed towards the associated comorbidities, and recent treatment modalities have been explored. A comprehensive comparison between FPLD2 and other FPLD subtypes can also be found in the present review. This review aimed to contribute towards augmenting knowledge of the natural history of FPLD2 by bringing together the main clinical research in this field.

Enfermedad arterial periférica y diabetes mellitus de tipo 2 en atención primaria / Peripheral arterial disease and diabetes mellitus type 2 in the primary care

Objetivo: Caracterizar la enfermedad arterial periférica en pacientes con diabetes mellitus tipo 2 e identificar su relación con variables sociodemográficas y clínicas. Métodos: Estudio descriptivo en 252 pacientes con diabetes melltus tipo 2. A todos se les midió el índice de presiones tobillo-brazo, para caracterizar la enfermedad y se les aplicó el cuestionario de Edimburgo. Las variables: índice de presiones tobillo-brazo, edad, sexo, años de evolución de la diabetes, factores de riesgo cardiovascular, claudicación intermitente. Resultados: La frecuencia del índice de presiones tobillo-brazo bajo fue de 37,2 por ciento (n= 99). Los factores asociados fueron el sexo, la edad, la hipertensión arterial y los años de evolución de la diabetes. El cuestionario de Edimburgo presentó una sensibilidad de 44,4 por ciento y una especificidad de 71,9 por ciento para detectar enfermedad arterial periférica sintomática. Conclusiones: La enfermedad arterial periférica se encuentra infradiagnosticada a pesar de la elevada frecuencia del índice de presiones tobillo-brazo bajo en pacientes con diabetes mellitus tipo 2; en Honduras hay escasa información, dado que no se implementan los métodos diagnósticos de manera rutinaria en pacientes con factores de riesgo para desarrollar la enfermedad, hasta que se encuentra muy avanzada. Hay relación directa de esta enfermedad con la edad, el sexo femenino, el tiempo de evolución de la diabetes mellitus y la hipertensión arterial. El cribado sistemático a través del índice tobillo-brazo identifica más individuos de alto riesgo candidatos a un control intensivo de sus factores de riesgo cardiovascular y facilita la búsqueda activa de enfermedad vascular en otros territorios(AU)

Objective: To characterize the peripheral arterial disease in patients with diabetes mellitus type 2 and to identify its relation with socio-demographic and clinical variables. Methods: A descriptive study in 252 patients with diabetes mellitus type 2. To all of them it was measured the ankle-brachial pressure index to characterize the disease and it was applied the Edinburgh questionnaire. The variables were: ankle-brachial pressure index, age, sex, years of evolution of diabetes, cardiovascular risk factors, and intermittent claudication. Results: The frequency of the ankle- upper arm pressures index was 37.2% (n=99). The associated factors were sex, age, hypertension and the years of evolution of diabetes. The Edinburgh questionnaire had a sensitivity of 44.4 percent and a specificity of 71.9 percent to detect symptomatic peripheral arterial disease. Conclusions: Peripheral arterial disease is underdiagnosed in spite of the high frequency of the of ankle- upper arm pressure index in patients with diabetes mellitus type 2; in Honduras, there is scarce information since there are not routinely implemented the diagnostic methods in patients with risk factors for developing the disease, until it is very advanced. There is a direct relation of this disease with the age, the female sex, time of evolution of diabetes mellitus and hypertension. The systematic screening through the ankle-brachial index identifies more high-risk individuals which are candidates for intensive control of cardiovascular risk factors and it facilitates the active search of vascular disease in other territories(AU)